Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 4/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16981793 | 0.76 | PARP1 (0.66) | PARP1NR3C1HCRTR1HCRTR2MAPK14 | |
| SCHEMBL25485607 | 0.73 | PARP1 (0.66) | PARP1HCRTR1HCRTR2MAPK14NPSR1 | |
| SCHEMBL3360298 | 0.71 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MAPK14MAPT | |
| SCHEMBL26930777 | 0.70 | PARP1 (0.54) | PARP1HCRTR1HCRTR2MAPK14 | |
| SCHEMBL1502069 | 0.69 | PARP1 (1.00) | PARP1HCRTR1HCRTR2MAPT | |
| SCHEMBL729580 | 0.69 | PARP1 (0.74) | PARP1HCRTR1HCRTR2MAPK14 | |
| SCHEMBL1021074 | 0.68 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MAPK14MAPT | |
| Hydrochloric Acid SCHEMBL7265489 | 0.68 | PARP1 (0.72) | PARP1HCRTR1HCRTR2MAPK14 | |
| SCHEMBL31468360 | 0.68 | PARP1 (0.57) | PARP1HCRTR1HCRTR2MAPK14SSTR4 | |
| SCHEMBL4573135 | 0.68 | KCNH2 (0.38) | PARP1NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-09-18 | — | — | US | disclosed |
| WO-2008052808-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1917963-A1 | Cyclic phenyl-substituted indazols, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227820-A1 | CYCLIC PHENYL-SUBSTITUTED INDAZOLS, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGIS, PTGS1, PTGES | PARP1 1391/4885NR3C1 865/4885HCRTR1 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.